论文部分内容阅读
目的:评价131I用于治疗自主功能性甲状腺腺瘤(AFTA)的临床疗效。方法:选取2008年4月至2012年6月于我院就诊治疗的AFTA患者34例,采用口服131I进行治疗,分别于治疗前及治疗后3、6、12个月检测血清T3、T4、TSH、FT3、FT4的水平,并经甲状腺显像及B超检查观察腺瘤的变化情况。结果:与治疗前相比,治疗后血清T4、T3、FT4、FT3的含量显著降低(P<0.05);TSH水平显著升高(P<0.05),且随着治疗时间的延长逐渐升高。34例患者的总治疗有效率为94.12%,仅2例出现甲状腺功能低下;治疗后患者的腺瘤平均直径显著减小(P<0.05),治疗3个月后甲状腺热结节消失;治疗后3、6、12个月患者的甲状腺功能复常率分别为70.69%、79.41%、91.18%;没有严重并发症发生。结论:口服131I对于AFTA具有良好的临床疗效,且安全可靠,值得在临床广泛应用。
Objective: To evaluate the clinical efficacy of 131I in the treatment of autonomic thyroid adenoma (AFTA). Methods: Totally 34 AFTA patients treated in our hospital from April 2008 to June 2012 were treated with oral 131I. Serum T3, T4 and TSH were measured before treatment and at 3, 6 and 12 months after treatment , FT3, FT4 levels, and thyroid imaging and B ultrasound examination of adenoma changes. Results: Compared with those before treatment, the levels of T4, T3, FT4 and FT3 in serum were significantly decreased (P <0.05) and the levels of TSH were significantly increased (P <0.05), and gradually increased with the prolongation of treatment time. The total effective rate was 94.12% in 34 patients and only 2 patients had hypothyroidism. After treatment, the mean diameter of adenoma was significantly reduced (P <0.05), and the thermal nodules disappeared after 3 months of treatment. After treatment, Thyroid function abnormalities were 70.69%, 79.41% and 91.18% at 3, 6 and 12 months respectively; no serious complications occurred. Conclusion: Oral 131I has good clinical efficacy for AFTA, and is safe and reliable. It is worth widely used in clinical practice.